BLOOD GLUCOSE TARGET ACHIEVEMENT AND ANTIDIABETES REGIMEN IN TYPE-2 DIABETIC GERIATRIC PATIENTS

Budi Suprapti*, Nony Vilaningtyas, Wenny Putri Nilamsari, Jusri Ichwani

Department of Clinical Pharmacy, Faculty of Pharmacy, Airlangga University Surabaya, Jl. Dharmawangsa dalam, Surabaya 60286

Sub Division of Geriatric, Internal Department, dr. Soetomo General/Teaching Hospital, Surabaya, Indonesia

Submitted: 11-11-2013  
Revised: 03-02-2014  
Accepted: 05-03-2014

*Corresponding author  
Budi Suprapti  
Email: budiprapti@yahoo.co.id

ABSTRACT  
Diabetes mellitus (DM) is a leading caused morbidity in geriatric patients. The prevalence of type-2 DM is more than 90% of DM population and increase with age, and half of those patients were geriatric. Blood glucose (BG) control is important for prevention diabetes complications, but attention must be given in geriatric patients due to the increasing susceptibility to risk of hypoglycemia. The aim of this study was to identify BG achievement in diabetic geriatric patients and its therapeutic management. This study was done in Outpatient Geriatric Clinic, Dr. Soetomo General Hospital Surabaya Indonesia in the period of March to June, 2012. The inclusion criteria were type-2 diabetic geriatric patients with/without diabetic complication that received antidiabetic therapy and had BG data. The results from 165 patients showed that BG target achieved by 53% patients, 41% patients not achieved the target, while 6% patients in risk of hypoglycemia. Management therapy for patients with achieved BG target was done by (1) continued therapy as before, (2) increasing dosage regimen for patients with BG already in the target but still within the upper limit target or decrease dosage regimen for patients with BG in lower limit target to avoid hypoglycemia, (3) change type of medication for patients who experienced side effects. Meanwhile, from all patients that failed to achieve BG target there were some patients received additional medications and regimen changes, but the rest of those didn’t receive any additional medication or regimen changes, which were many of them eventually became one of the drug-related problems in this patient group. In conclusion, there were still quite large number patients that did not achieve BG target, the therapy management changes were made based on BG profile and there were drug related problems related to dosage regimen that needs pharmaceutical care intervention.

Key words: antidiabetic, regimen, blood glucose achievement, geriatric

INTRODUCTION  
Elderly patients usually present with one or more degenerative diseases and about 60% of the population had a history of at least one chronic disease including diabetes (Naughton and Feely, 2006). Diabetes is a common chronic disease with the prevalence increases with age (Fauci et al., 2008) and one of major cause of disability in the elderly (Triplitt et al., 2008). The prevalence of type 2 diabetes in the elderly is likely to increase, generally 90% of adult patients with diabetes, diagnosed as type 2 diabetes and 50% of that were older than 60 years (Gustaviani, 2006). Because of carbohydrate metabolism disorder, elderly is more prone to suffer from diabetes (Chun, 2003).

Blood sugar control in diabetes mellitus is essential to prevent a variety of chronic complications, both microvascular, macrovascular and neuropathic. However, special precaution should be given because there are a lot of changes in pharmacokinetics and pharmacodynamics that can bring the patient to a greater risk of hypoglycemia (Triplitt et al., 2008). Study Action to Control Cardiovascular Risk in Diabetes (ACCORD) conducted a study in a population with an average age of 62 years with diabetes since 10 years, comparing the strategy of intensive...
glycemic (HbA1c <6.0%) with a standard (target HbA1c of 7.0%). Results showed the risk of death was higher in the intensive group and likely caused by hypoglycemia (257 vs. 203 events deceased) (Gerstein et al., 2008). This study was conducted to identify the blood glucose achievement in geriatric patients with diabetes mellitus and therapeutic management.

**MATERIAL AND METHODS**

This is a prospective cross-sectional study, conducted at outpatient clinic Dr. Soetomo Hospital Surabaya Indonesia from March to June 2012, using secondary data. The inclusion criteria were all geriatric patients with type-2 diabetic, with/without diabetic complication, had received antidiabetic therapy and complete BG data. Sampling was done by simple random sampling technique to obtain 165 samples of research. The methodology of this study was approved by Ethic Committee Dr. Soetomo Teaching Hospital, Surabaya Indonesia.

**RESULT AND DISCUSSION**

From 165 patients enrolled, there were higher female patients than males (64% vs. 36%) (Table I). National Commission on the Elderly in 2010 reported that population of older women in Indonesia was almost 60%, higher than men. The patients were grouped into middle age patient (60-65), old age (66-75), very old age (76-85) and oldest old age (> 85) (Shephard, 1998) (Table I).

**Table I. Characteristic of type 2 DM patients in geriatric outpatients Dr. Soetomo Hospital**

| No | Characteristic | Number of Patients (%) |
|----|----------------|------------------------|
| 1. | Gender:        |                        |
|    | Female         | 106(64)                |
|    | Male           | 59(36)                 |
|    | Total          | 165(100)               |
| 2. | Age (Year):    |                        |
|    | 60-65          | 32(19)                 |
|    | 66-75          | 87(53)                 |
|    | 76-85          | 44(27)                 |
|    | >85            | 1(1)                   |
|    | Total          | 165(100)               |

Elderly is susceptible to chronic complications of diabetes that can increase morbidity and mortality (Kurniawan, 2010). A patient may experience more than one complication or comorbid. Previous research result showed most complications were cardiovascular disease (42%) and stroke (18%). Cardiovascular disease and stroke are the macrovascular complications caused by advanced glycation end (AGEs) products (Funk, 2010). In addition, most comorbid experienced by patients was hypertensive as much as 86%.

Treatment of type 2 DM is started with a non-pharmacological therapy (healthy lifestyle) or OAD monotherapy. If it fails to decrease BG, then a combination of 2 to 3 oral antidiabetics (OAD) are given. If the target is not achieved with the combination then the combination of basal insulin and OAD is recommended. When the latest combination fails to control glucose levels, then the OAD is discontinued and insulin combination therapy is started. Therapy is stated to fail when BG target cannot be achieved in 2-3 months at each level (PERKENI, 2011).

Result showed that from totally antidiabetes drug used, 86% were OADs and 14% were insulin, administered as single or in combination. The use of insulin was lower than OAD because insulin therapy requires special considerations including the ability to use insulin injections, recognizing and managing the condition of hypoglycemia, as well as the visual function, cognitive, availability of caregiver and patient financial capability (Neumiller and Setter, 2009).

Table II demonstrates that most drugs used were sulfonylureas, as much as 80 % of the patients. The sulfonylureas were effective in achieving blood glucose target in elderly patients (Abbatecola and Paolisso, 2009). However, patients should pay special caution because hypoglycemia risk increases in old age.

Glimepirid is a long-acting sulfonylurea with half life of 9h, duration of action 24h and has an active metabolite (Wickersham, 2009, Sweetman, 2009). Glimepirid is eliminated by liver and kidney by 60% (Lee, 2009, Sweetman, 2009). Kidney function tends to decline in old age leading to decrease of drug excretion (Dipiro et al., 2008).
Blood Glucose Target Achievement and Antidiabetes

To avoid the risk of hypoglycemia, short-acting sulfonylurea is preferred because of less hypoglycemia risk than that of long-acting (Lee, 2009). However, glimepirid is still used because glimepirid can be administered once a day that can improve patient compliance (Neumiller and Setter, 2009). Short acting sulfonylureas are gliblazide and gliclazide because they have short duration of action and without active metabolites. Glikuidon and gliclazide can be used in patients with renal disorder as they excreted more through the liver (Lee, 2009). The use of single and combination therapy can be seen in Figure 1.

The dose and regimen of oral anti diabetics can be seen in table III, whereas for insulin is listed in table IV. Glimepirid dose was 0.5 to 4mg and used 1-2x per day (Table IV). Glimpred maximum dose is 6mg (PERKENI, 2011). Gliclazide dose was 30-240mg and the regimen were 1x1, 2x1, 2-1-0 while the maximum dose is 320mg with frequency use 1-2x a day (PERKENI, 2011). Regimen 2-1-0 was appropriate if the total dose needed is more than 160mg/day (Sweetman, 2009). Glikuidon dose given to the patients was 15-60mg divided in 1-2x a day and 30mg with regimen 2-1-0, 1-1/2-0. Maximum dose of glikuidon is 120mg which divided in 2-3x daily (Sweetman, 2009). In order to achieve optimal control BG with minimal side effects, the dose was adjusted individually.

In this study, acarbose dose used were 50 and 100mg with frequency of usage was1-3x per day (Table III) while, maximum dose recommended is 300mg divided in 1-3x per day.
Acarbose is not recommended in patients with renal failure with creatinine clearance ≤ 24mL/min (Neumiller and Setter, 2009). Metformin dose used in this study was 500mg with a frequency of 1-3x per day. Metformin does not cause side effects hypoglycemia (Neumiller and Setter, 2009). Metformin can lose weight so that it can be used in patients who are obese (McEvoy, 2008).

Thiazolidinediones used in this study was pioglitazone (1 patient) (Table III). Patients who have congestive heart failure stage III and IV should be aware when using thiazolidinediones, because it can cause edema (Neumiller and Setter, 2009). Pioglitazone has a lower risk of myocardial infarction compared to rosiglitazone (Neumiller and Setter, 2009). In addition, pioglitazone may improve endothelial function, increase levels of HDL (Triplitt et al., 2008). The dose used in this study was 15mg once daily with the maximum dose is 45mg/day (Wickersham, 2009).

Geriatric patients require insulin in hyperglycemic conditions which are difficult to control and condition which are contraindicated with OAD (Tanwani, 2011). In this study, rapid-acting insulin was used by 6.67% patients, while long-acting insulin was used by 11.52% patients whereas premixed insulin (70% aspart protamine, 30% aspart) was used by 7.88% patients (Table II). Elderly patients with irregular eating schedule can benefit from the use of rapid-acting insulin (Tanwani, 2011). Long-acting insulin has a long duration of action and used once a day making patient compliant to increase. In addition, insulin glargine reduced the incidence of nocturnal hypoglycaemia hence appropriate for the elderly who are at greater risk of hypoglycemia (Neumiller and Setter, 2009). The advantage of premixed insulin is more flexible because it lowers the frequency of intensive insulin injection (Tanwani, 2011).

Table III. Dose and regimen of oral antidiabetes in geriatric outpatients Dr. Soetomo Hospital

| Drug    | Dose   | Regimen                   |
|---------|--------|---------------------------|
| Glimepirid | 1-4 mg | 1x1 morning 1x ½ 2x1  |
| Gliklazid | 30-80 mg | 1x1 2x1 or 2-1-0         |
| Glikuidon | 30 mg   | 1x1 or 1/2 2x1 or 2-1-0 atau 1- ½ -0 |
| Metformin | 500 mg  | 1-3x1 evening            |
| Pioglitazon | 15 mg   | 1x1                       |

Note : -Every patient can received more than 1 OAD.

Table IV. Dose and regimen of subcutan insulin in geriatric outpatients Dr. Soetomo Hospital

| Drug               | Dose   | Regimen                   |
|--------------------|--------|---------------------------|
| Aspart             | 6-14 U | 3x                         |
| Glulisine          | 12 U   | 3x                         |
| Glargine           | 10-20U | 1x morning or evening     |
| Detemir            | 8-20U  | 1x morning or evening     |
| 70 Aspart Protamin/30 Aspart | 12-20U | 12-0-12 U 12-0-14 U 14-0-16 U 24-0-10 U |
|                   |        | 14-0-16 U 24-0-10 U 24-0-20 U |
|                   |        |                            |
Blood Glucose Target Achievement and Antidiabetes

Table V. Blood glucose achievement of type 2 DM patients in geriatric outpatients Dr. Soetomo Hospital Surabaya

| No. | Blood Glucose Achievement | Management Therapy | Number of patient (%) | Reason |
|-----|----------------------------|---------------------|-----------------------|--------|
| 1.  | Achieved Target (FPG 100-125 mg/dl, 2hPP 145-180mg/dl, CPG ≤ 180mg/dl) | No Change | 65 (39.4) | Target has been achieved |
|     |                             | Reduce Regimen /Reduce the number of drug | 7 (4.2) | Blood Glucose Level was close to the lower limit |
|     |                             | Increase Regimen/ Add other drugs | 11 (6.7) | Blood Glucose Level was close to the upper limit |
|     |                             | Change Drug | 5 (3.0) | Patients suffered from adverse drug reactions |
|     |                             | **Total** 88(53.3) | \ | \ |
| 2.  | Not achieved (FPG >125 mg/dl, CPG&2hPP > 180mg/dl) | No Change | 35 (21.2) | - 20.6% were close to target |
|     |                             | Increase Regimen/Add other drugs | 18 (10.9) | - 2.4% needed additional drug because blood glucose levels were far from the target |
|     |                             | Reduce Regimen/Reduce the number of drug at Change Drug | 7 (4.2) | The previous regimen failed to achieve target, so the drug was changed |
|     |                             | **Total** 67 (40.6) | | |
| 3.  | Hypoglycemia Risk (≤ 110 mg/dl) | - | 10 (6.1) | 1.8% patients had blood glucose levels very low. Therefore, the drug were switched to another drug that has lower potency. |

Decision to give rapid-acting insulin is based on the 2h postprandial glucose levels whereas a long-acting insulin levels is based on fasting plasma glucose/casual plasma glucose. In this study, insulin dosage given to patients varies (Table IV) and adjusted based on individual response, which was assessed from the glucose levels. Regimen instructed to patients were appropriate include rapid acting 3x daily, long acting insulin 1x daily at night or in the morning while the premixed insulin used 1-2x a day in the morning and evening (Table IV).

The patients were routinely checked the BG levels (CPG, FPG and 2hPP) every month. For patients older than 60 years, the target achievement can be higher than adults with Type 2 DM. Target achievement of FPG is 100-125mg/dL, 2hPP is 145-180mg/dL (PERKENI), 2011) and CPG is less than 180mg/dL (ADA, 2012). The risk of hypoglycemia may increase in patients with
very tight control of glucose levels that is ≤ 110mg/dL (Wiener et al., 2008).

In this study as much as 53.3% patients achieved blood glucose levels, 40.6% failed to achieve and 6.1% suffered from hypoglicemia. Management for the patients is depend on BG level and directed individually. From total patients who achieved target, 39.4% patients had no change of therapy, 4.2% patients was reduced regimen or reduced drug because glucose levels were close to lower limit and 9.7% patients were increased regimen or given additional drug or changed to another drug that more potent because glucose levels were close to upper limit (Table V).

From total patients who failed to achieve target 21.2% patients had no change of therapy. From those patients, 20.6% were close to target and 2.4% patients were still far from target, therefore it was drug related problem. As much as 10.9% failed to achieve target received dose escalation or additional drug. Reduced regimen or reduced numbers of drugs were done in 4.2% patients who were sometimes experienced from hypoglycemia/adverse drug reaction. Meanwhile the rest 4.2% patients had changed the drugs therapy. Some patients (6.1%) who at risk of hypoglycemia (BG <110 mgdL, for geriatric) were changed to another drug that has lower potency to decrease risk of hypoglycemia (Table V).

**CONCLUSION**

The number of diabetic geriatric patients who did not achieve the target BG is still quite large, therapy management changes made based on BG profile individually and there are drug related problems in dosage regimen that needs pharmaceutical care intervention.

**ACKNOWLEDGMENT**

We are grateful to the Department Clinical Pharmacy, Faculty of Pharmacy, Airlangga University Surabaya and Sub Division of Geriatric, Internal Department, dr. Soetomo General/Teaching Hospital, Surabaya for support.

**REFERENCES**

Abbatecola, AM. and Paolisso, G. 2009. Diabetes Care Targets in Older Persons. *Diabetes Res Clin Pract*, 86S: S35-S40.

Chun, AK. 2003. Diabetes Mellitus. In : Soriano, R.P (Ed), *Fundamentals of Geriatric Medicine A Case Based Approach*. New York: Springer, pp. 437-449.

Fauci, AS., Braunwald, E., Kasper, DL., Hauser, SL., Longo, DL., et al., 2008. *Harrison’s Principles of Internal Medicine*. 17th Ed. New York: McGraw Hill.

Funk, JL. 2010. Disorder of The Endocrine Pancreas. In: Mc.Phee S.J (Ed), *Pathophysiology of Disease An Introduction to Clinical Medicine*. 6th Ed. New York: Mc Graw Hill.

Gustaviani, R. 2006. Diagnosis dan Klasifikasi Diabetes Melitus. *In : Sudoyo, A.W. & Setiyohadi, B (Eds), Buku Ajar Ilmu Penyakit Dalam Edisi IV jilid III*. Jakarta: Balai Penerbit FKUI, pp. 1879-1885.

Gerstein, HC., Miller, ME. and Byington, R.P. 2008. For The Action To Control Cardiovascular Risk In Diabetes Study Group. Effects Of Intensive Glucose Lowering In Type 2 Diabetes. *N Engl J Med*. 358:2545–2559.

Kurniawan, I. 2010. Diabetes Melitus Tipe 2 pada Usia Lanjut. Majalah Kedokteran Indonesia, 60 : 12.

Lee, FTH. 2009. Advances in Diabetes Therapy in The Elderly. *Journal of Pharmacy Practice and Research (JPPR)*, 39(1) : 63-67.

McEvoy, GK. 2008. *AHFS Drug Information*. Bethesda : American Society of Health System Pharmacist.

Neumiller, JJ. and Setter, SM. 2009. Pharmacologic Management of The Older Patient. *Am. J. Geriatr. Pharmacother*, 7(6) : 324-342.

PERKENI (Pengurus Besar Perkumpulan Endokrinologi Indonesia). 2011. *Konsensus Pengelolaan dan Pencegahan Diabetes Mellitus Tipe 2 Di Indonesia*. Pengurus Besar Perkumpulan Endokrinologi Indonesia.

Sweetman, SC. 2009. *Martindale: The Complete Drug Reference*. 36th Ed. London: Pharmaceutical Press.

Shephard, RJ. 1998. Aging and Exercise. *In: Fahey, T. D. (Ed), Encyclopedia of Sports Medicine and Science*, Date of published March, 7 1998, access from Society for Sport Science: http://sportsci.org.
Tanwani, LK. 2011. Insulin Therapy in the Elderly Patient With Diabetes. *Am. J. Geriatr. Pharmacother.* 9(1): 24-33.

Triplitt CL, Reasner CA., Isley NL., 2008, Diabetes Mellitus, in Dipiro JT et al, *Pharmacotherapy: A Pathophysiology Approach*, 7th ed., Mc Graw Hill Medical, New York, 1205-1241.

Wickersham, RM. 2009. *Drug Facts and Comparison Pocket Version.* California : Wolters Kluwer Health, pp. 176-210.

Wiener, RS., Wiener, DC., and Larson, RJ. 2008. Benefits and Risks of Tight Glucose Control in Critically Ill Adults. *JAMA*, 300(8): 933-944.